Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination Therapy in P-III FeDeriCa Study for HER2+ve Breast Cancer

 Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination Therapy in P-III FeDeriCa Study for HER2+ve Breast Cancer

Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination Therapy in P-III FeDeriCa Study for HER2+ve Breast Cancer

Shots:

  • The P-III FeDeriCa study involves assessing of Perjeta (pertuzumab) and Herceptin (trastuzumab) as FDC in SC formulation + CT (IV) vs its standard IV Infusion formulation + CT in patients with HER2-positive eBC, being treated with neoadjuvant and adjuvant setting
  • The P-III FeDeriCa study results: reduction in the time spent for receiving treatment, loading dose & maintenance dose (8min. & 5min. vs 150min. & 60min.-150min.); safety profile is consistent with IV regimen respectively
  • The FDC regimen combines Perjeta and Herceptin via Halozyme Therapeutics’ Enhanze drug delivery technology, which is based on rHuPH20 enzyme, work by optimizing SC drug delivery to co-administer therapies

Click here to­ read full press release/ article | Ref: Roche | Image: ID Works Global

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post